Zydus, CSIR-CDRI Lucknow to develop drug for Chronic Kidney Disease induced Osteoporosis Ruchika Sharma1 Oct 2024 11:30 AM ISTAhmedabad: Zydus Lifesciences Ltd, Ahmedabad has signed a collaborative research agreement with Central Drug Research Institute, Lucknow for the...
Sun Pharma to now offer Desidustat, first oral treatment for CKD-associated anaemia in India under brand Rytstat Ruchika Sharma30 Oct 2023 12:50 PM ISTMumbai: Strengthening its position in the chronic kidney disease space, Sun pharma is now going to offer Desidustat, the first-of-its-kind oral...
Zydus Lifecsciences begins Desidustat Phase IV trial in patients with CKD induced anemia Ruchika Sharma31 Aug 2022 12:30 PM ISTDesidustat is currently approved in India as Oxemia for the treatment of anemia in Chronic Kidney Disease (CKD) patients.
Zydus Life Desidustat gets CDSCO panel nod to treat Anaemia in Kidney Patients Dr. Divya Colin27 July 2022 6:00 PM ISTNew Delhi: In a significant development, Zydus Life has received approval from the Subject Expert Committee (SEC) functional under the Central Drug...
Zydus Lifesciences publishes phase 3 trials of Desidustat in American Journal of Nephrology Ruchika Sharma25 April 2022 12:51 PM ISTDesidustat is currently approved only in India as Oxemia for patients with CKD induced anemia.
Zydus to launch Desidustat breakthrough treatment for Anemia in CKD patients under brand name Oxemia MD Bureau7 March 2022 12:04 PM ISTOxemia is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor.
Zydus seeks DCGI approval for Desidustat to treat anaemia in kidney patients Ruchika Sharma23 Nov 2021 1:15 PM ISTAhmedabad: Pharma major, Zydus Cadila, today announced that the company has submitted the New Drug Application (NDA) to the Drug Controller General...
Zydus Cadila completes patient enrolment for 2 Phase III trials of Desidustat Ruchika Sharma6 Feb 2021 10:00 AM ISTAhmedabad: Zydus Cadila, global pharmaceutical company, has recently announced that the company has completed patient enrolment in DREAM-ND and...
Zydus Cadila Desidustat shows efficacy, safety in treating Hypoxia in COVID-19 patients Ruchika Sharma26 Jan 2021 11:00 AM ISTAhmedabad: Drug major, Zydus Cadila, has recently announced that the company has received positive results from Phase 2(b) studies of Desidustat...
Zydus Cadila Desidustat gets USFDA nod to initiate clinical trials on cancer patients Ruchika Sharma24 July 2020 1:33 PM ISTAhmedabad: Zydus has received approval from the USFDA, to initiate clinical trials of Desidustat in Chemotherapy Induced Anemia...
COVID-19 Drug: Zydus Cadila gets Mexican nod to test Desidustat Ruchika Sharma6 July 2020 12:21 PM ISTDesidustat (a hypoxia inducible factor prolyl hydroxylase inhibitor, currently undergoing Phase 3 trials) mimics the physiologic effect of altitude on...
